<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cold Spring Harb Mol Case Stud</journal-id>
<journal-id journal-id-type="iso-abbrev">Cold Spring Harb Mol Case Stud</journal-id>
<journal-id journal-id-type="hwp">cshmcs</journal-id>
<journal-id journal-id-type="pmc">cshmcs</journal-id>
<journal-id journal-id-type="publisher-id">cshmcs</journal-id>
<journal-title-group>
<journal-title>Cold Spring Harbor Molecular Case Studies</journal-title>
</journal-title-group>
<issn pub-type="epub">2373-2873</issn>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28655807</article-id>
<article-id pub-id-type="pmc">5701310</article-id>
<article-id pub-id-type="doi">10.1101/mcs.a001925</article-id>
<article-id pub-id-type="medline">WalshMCS001925</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Rapid Cancer Communication</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Germline <italic>BRCA2</italic> mutations detected in pediatric sequencing studies impact parents’ evaluation and care</article-title>
<alt-title alt-title-type="left-running">Pediatric <italic>BRCA2</italic> mutations impact parents’ care</alt-title>
<alt-title alt-title-type="right-running">Pediatric <italic>BRCA2</italic> mutations impact parents’ care</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Walsh</surname>
<given-names>Michael F.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kennedy</surname>
<given-names>Jennifer</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Harlan</surname>
<given-names>Megan</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kentsis</surname>
<given-names>Alex</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shukla</surname>
<given-names>Neerav</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Musinsky</surname>
<given-names>Jacob</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roberts</surname>
<given-names>Stephen</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kung</surname>
<given-names>Andrew L.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Robson</surname>
<given-names>Mark</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kushner</surname>
<given-names>Brian H.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Meyers</surname>
<given-names>Paul</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Offit</surname>
<given-names>Kenneth</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
</contrib-group>
<aff id="af1"><label>1</label>Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA;</aff>
<aff id="af2"><label>2</label>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA</aff>
<author-notes>
<corresp>Corresponding author: <email>walshm2@mskcc.org</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>11</month>
<year>2017</year>
</pub-date>
<volume>3</volume>
<issue>6</issue>
<elocation-id>a001925</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>2</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>6</day>
<month>6</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>
<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.cshlp.org/site/misc/terms.xhtml">© 2017 Walsh et al.; Published by Cold Spring Harbor Laboratory Press</ext-link>
</copyright-statement>
<copyright-year>2017</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-NonCommercial License</ext-link>, which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="WalshMCS001925.pdf"></self-uri>
<abstract>
<p>There has been no indication to test for <italic>BRCA1/2</italic> in children (with the rare exception of Fanconi anemia) as screening begins in adult years and there is a potential to induce anxiety related to adult-onset cancers. However, in the setting of pediatric cancer, with increasing utility and frequency of companion tumor-normal sequencing without regard for phenotype and with <italic>BRCA1/2</italic> included in tumor profiling panels, germline mutations in <italic>BRCA1/2</italic> and other DNA damage repair genes have been found. When mutations in these genes are revealed, there are implications for immediate family members. Here we present two children in whom <italic>BRCA2</italic> mutations identified through tumor sequencing prompted parental genetic testing and medical action. These cases illustrate the potential importance of including a matched normal DNA sample when performing tumor profiling of pediatric cancer patients to ensure optimal care.</p>
</abstract>
<kwd-group>
<kwd>neuroblastoma</kwd>
<kwd>osteosarcoma</kwd>
</kwd-group>
<funding-group>
<award-group id="funding-1">
<funding-source>
<institution-wrap>
<institution>National Institutes of health (NIH) </institution>
<institution-id institution-id-type="open-funder-registry">10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
<award-id>P30 CA008748</award-id>
</award-group>
<award-group id="funding-2">
<funding-source>
<institution-wrap>
<institution>National cancer Institute (NCI) </institution>
<institution-id institution-id-type="open-funder-registry">10.13039/100000054</institution-id>
</institution-wrap>
</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="7"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>CASE PRESENTATION</title>
<sec id="s1a">
<title>Patient 1</title>
<p>An 11-yr-old boy with localized osteosarcoma in the left proximal humerus presented with intermittent pain in the affected arm and underwent a definitive resection of a biopsy-proven osteosarcoma. Mutation panel sequencing of the tumor was performed by Foundation Medicine that revealed a <italic>BRCA2</italic> Q2354* (<xref ref-type="bibr" rid="WALSHMCS001925C9">Frampton et al. 2013</xref>). Given the potential implications of a germline <italic>BRCA2</italic> mutation for family members, parental blood samples were drawn, revealing the patient's 40-yr-old mother was found to carry the <italic>BRCA2</italic> mutation. This finding led to her decision for a risk-reductive mastectomy and bilateral salpingo oophorectomy. Although the patient's grandmother had a history of breast cancer, her age of onset did not raise suspicion for a predisposition to cancer or indicate germline testing at the time of her diagnosis (<xref ref-type="fig" rid="WALSHMCS001925F1">Fig. 1</xref>A).</p>
<fig id="WALSHMCS001925F1" orientation="portrait" position="float">
<label>Figure 1.</label>
<caption>
<p>Children identified harboring <italic>BRCA2</italic> mutations prompting maternal testing and care. (<italic>A</italic>) Patient 1. (<italic>B</italic>) Patient 2.</p>
</caption>
<graphic xlink:href="WalshMCS001925_F1"></graphic>
</fig>
</sec>
<sec id="s1b">
<title>Patient 2</title>
<p>A 2 yr-old boy with global developmental delay presented with a 3- to 4-wk history of respiratory symptoms. Chest computed tomography (CT) revealed a 9.3 cm × 8.7 cm mediastinal mass. An iodine-123-meta-iodobenzylguanidine (MIBG) scan showed uptake compatible with neuroblastoma that was histologically confirmed.</p>
<p>Foundation Medicine tumor sequencing revealed a BRCA2 p.Y2215fs* mutation. In-house paired tumor-normal sequencing, MSK-IMPACT was also performed utilizing a control germline blood sample for tumor variant calling. Of note, the practice at Memorial Sloan Kettering Cancer Center (MSKCC) is to not report germline mutations detected by MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets) unless specific consent to return germline results has been provided. In this instance, MSK-IMPACT testing did not report the BRCA2 p. Y2215fs mutation; prompting the suspicion that the <italic>BRCA2</italic> mutation reported by Foundation Medicine was constitutional. The boy's family history was notable for his mother having been diagnosed with squamous cell carcinoma at age 34 yr, his maternal grandmother diagnosed with basal cell carcinoma at age 40 yr, his maternal great grandmother diagnosed with breast cancer in her 50s, and a paternal aunt diagnosed with breast cancer at age 34 yr (<xref ref-type="fig" rid="WALSHMCS001925F1">Fig. 1</xref>B). Parental testing revealed the child's mother harbored the medically actionable BRCA2 p.Y2215fs* mutation, which subsequently led her to undergo magnetic resonance imaging (MRI) and mammography breast screening and to seek consultation with breast and gynecologic specialists.</p>
</sec>
</sec>
<sec id="s2">
<title>TECHNICAL ANALYSIS</title>
<p>In Patient 1, the BRCA2 p.Q2354* germline mutation identified through tumor testing (performed by Foundation Medicine) and, in Patient 2, the BRCA2 <italic>p.</italic> Y2215fs* germline mutation identified by tumor testing (performed by Foundation Medicine and MSKCC IMPACT testing) were confirmed by targeted site-specific testing at the commercial laboratory GeneDx (<xref ref-type="bibr" rid="WALSHMCS001925C9">Frampton et al. 2013</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C2">Cheng et al. 2015</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C26">Susswein et al. 2016</xref>).</p>
</sec>
<sec id="s3">
<title>VARIANT INTERPRETATION</title>
<p>The Q2354* variant in <italic>BRCA2</italic> is entered five times in ClinVar and annotated as pathogenic (<xref ref-type="bibr" rid="WALSHMCS001925C16">Landrum et al. 2016</xref>). The variant is linked with Database for Short Genetic Variations (dbSNP): 80358936 and the National Center for Biotechnology Information (NCBI) 1000 Genomes browser rs80358936. This specific truncation mutation is not annotated by the Evidenced-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA), the Consortium of Investigators of Modifiers of <italic>BRCA1/2</italic> (CIMBA), or the Breast Cancer Information Core (BIC) (<xref ref-type="bibr" rid="WALSHMCS001925C10">Genomes Project et al. 2010</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C25">Spurdle et al. 2012</xref>). ENIGMA describes the variant as predicted to encode a truncated nonfunctional protein. Moreover, the mutation is reported in the literature as occurring in a Spanish patient with breast cancer, and the commercial laboratory InVitae has asserted this variant as pathogenic (<xref ref-type="bibr" rid="WALSHMCS001925C8">Duran et al. 2003</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C13">Hirsch et al. 2004</xref>).</p>
<p>The p.Y2215fs* <italic>v</italic>ariant in <italic>BRCA2</italic> is predicted to encode a truncated nonfunctional protein and termination mutations at this codon (Y2215*) are annotated three times as pathogenic in ClinVar (<xref ref-type="bibr" rid="WALSHMCS001925C16">Landrum et al. 2016</xref>). Termination variants at this codon are linked with dbSNP: 80358892, and the NCBI 1000 Genomes browser rs80358892 and the BIC have asserted termination variants at this location as pathogenic (<xref ref-type="bibr" rid="WALSHMCS001925C10">Genomes Project et al. 2010</xref>). However, this specific truncation mutation is not annotated in the CIMBA (<xref ref-type="bibr" rid="WALSHMCS001925C25">Spurdle et al. 2012</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C22">Rebbeck et al. 2016</xref>).</p>
</sec>
<sec id="s4">
<title>SUMMARY</title>
<p>Here we present two childhood cancer patients, for whom the results of tumor sequencing prompted parental testing for germline <italic>BRCA2</italic> mutations, leading to genetic counseling and medical action in both mothers harboring the germline BRCA2 variants.</p>
<p><italic>BRCA1</italic> and <italic>BRCA2</italic> are proven autosomal dominant breast, ovarian, pancreatic, and prostate cancer predisposition genes (<xref ref-type="bibr" rid="WALSHMCS001925C18">Neuhausen et al. 1996</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C15">Kauff et al. 2001</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C21">Pritchard et al. 2016</xref>). Pediatric phenotypes are known to result when a child inherits biallelic mutations in <italic>BRCA2</italic>, and rarely in <italic>BRCA1</italic> (i.e., the recessive disorder Fanconi anemia) (<xref ref-type="bibr" rid="WALSHMCS001925C4">D'Andrea and Grompe 1997</xref>, <xref ref-type="bibr" rid="WALSHMCS001925C5">2003</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C14">Howlett et al. 2002</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C23">Sawyer et al. 2015</xref>).</p>
<p>In pediatrics, the only indication to test for <italic>BRCA1/2</italic> has been in the context of Fanconi anemia given the potential to induce anxiety related to adult-onset cancers (<xref ref-type="bibr" rid="WALSHMCS001925C12">Green et al. 2013</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C23">Sawyer et al. 2015</xref>). Recently, with increasing companion tumor-normal sequencing performed, without regard for phenotype and with <italic>BRCA1/2</italic> included in tumor profiling panels, germline mutations in these and other DNA damage genes have been detected (<xref ref-type="table" rid="WALSHMCS001925TB1">Table 1</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C6">Dite et al. 2010</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C27">Walsh et al. 2014</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C17">Mody et al. 2015</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C29">Zhang et al. 2015</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C20">Parsons et al. 2016</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C24">Schrader et al. 2016</xref>). Pathogenic cancer predisposition gene mutations were found in 95/1120 (8.5%) pediatric cancer patients participating in the Pediatric Cancer Genome Project (PCGP), as compared to 1.1% of persons in the 1000 Genomes Project and 0.6% of the participants in the autism study (<xref ref-type="bibr" rid="WALSHMCS001925C3">Daly et al.</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C7">Downing et al. 2012</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C11">Genomes Project et al. 2015</xref>). However, given that a true incidence study comparing pediatric cancer patients with healthy controls has yet to occur and a uniform sequencing approach has not been deployed in all pediatric studies to date, it remains to be determined if heterozygous mutations in <italic>BRCA2</italic> detected in pediatric cancer patients are driver or passenger events (<xref ref-type="bibr" rid="WALSHMCS001925C19">Offit et al. 2003</xref>; <xref ref-type="bibr" rid="WALSHMCS001925C29">Zhang et al. 2015</xref>). Notably, the second most commonly mutated gene in the PCGP was <italic>BRCA2 (n</italic> = 6), and <italic>BRCA2</italic> mutations may be enriched in children cancer survivors compared with controls (Zhang et al. 2015; <xref ref-type="bibr" rid="WALSHMCS001925C28">Wang et al. 2017</xref>).</p>
<table-wrap id="WALSHMCS001925TB1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption>
<p>Review of germline <italic>BRCA1/2</italic> mutations detected in pediatric sequencing studies</p>
</caption>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" span="1"/>
<col align="char" span="1"/>
<col align="char" span="1"/>
<col align="char" span="1"/>
<col align="char" span="1"/>
<col align="char" span="1"/>
<col align="char" char="." span="1"/>
<col align="left" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Tumor type</th>
<th align="center" colspan="1" rowspan="1">Gene</th>
<th align="center" colspan="1" rowspan="1">Chr</th>
<th align="center" colspan="1" rowspan="1">Location</th>
<th align="center" colspan="1" rowspan="1">HGVS DNA ref</th>
<th align="center" colspan="1" rowspan="1">HGVS protein</th>
<th align="center" colspan="1" rowspan="1">Variant type</th>
<th align="center" colspan="1" rowspan="1">Germline platform</th>
<th align="center" colspan="1" rowspan="1">Allele frequency (normal)</th>
<th align="center" colspan="1" rowspan="1">Target coverage</th>
<th align="center" colspan="1" rowspan="1">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Osteosarcoma</td>
<td colspan="1" rowspan="1">
<italic>BRCA2</italic>
</td>
<td colspan="1" rowspan="1">Chr 13</td>
<td colspan="1" rowspan="1">32354913</td>
<td colspan="1" rowspan="1">G</td>
<td colspan="1" rowspan="1">p.Q2354*</td>
<td colspan="1" rowspan="1">Nonsense</td>
<td colspan="1" rowspan="1">Sanger</td>
<td colspan="1" rowspan="1">0.46</td>
<td colspan="1" rowspan="1">500×</td>
<td colspan="1" rowspan="1">This study</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Neuroblastoma</td>
<td colspan="1" rowspan="1">
<italic>BRCA2</italic>
</td>
<td colspan="1" rowspan="1">Chr 13</td>
<td colspan="1" rowspan="1">32340999</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">p.Y2215fs</td>
<td colspan="1" rowspan="1">Frameshift</td>
<td colspan="1" rowspan="1">Sanger</td>
<td colspan="1" rowspan="1">0.48</td>
<td colspan="1" rowspan="1">500×</td>
<td colspan="1" rowspan="1">This study</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Neuroblastoma</td>
<td colspan="1" rowspan="1">
<italic>BRCA1</italic>
</td>
<td colspan="1" rowspan="1">Chr 17</td>
<td colspan="1" rowspan="1">43124028</td>
<td colspan="1" rowspan="1">G</td>
<td colspan="1" rowspan="1">p.E23fs</td>
<td colspan="1" rowspan="1">Frameshift</td>
<td colspan="1" rowspan="1">WES</td>
<td colspan="1" rowspan="1">0.43</td>
<td colspan="1" rowspan="1">272×</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WALSHMCS001925C20">Parsons et al. 2016</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Anaplastic medulloblastoma</td>
<td colspan="1" rowspan="1">
<italic>BRCA1</italic>
</td>
<td colspan="1" rowspan="1">Chr 17</td>
<td colspan="1" rowspan="1">43094833</td>
<td colspan="1" rowspan="1">GT</td>
<td colspan="1" rowspan="1">p.V233fs</td>
<td colspan="1" rowspan="1">Frameshift</td>
<td colspan="1" rowspan="1">WES</td>
<td colspan="1" rowspan="1">0.5</td>
<td colspan="1" rowspan="1">272×</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WALSHMCS001925C20">Parsons et al. 2016</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Ewing sarcoma</td>
<td colspan="1" rowspan="1">
<italic>BRCA2</italic>
</td>
<td colspan="1" rowspan="1">Chr 17</td>
<td colspan="1" rowspan="1">32332757</td>
<td colspan="1" rowspan="1">G</td>
<td colspan="1" rowspan="1">p.D427fs</td>
<td colspan="1" rowspan="1">Frameshift</td>
<td colspan="1" rowspan="1">WES</td>
<td colspan="1" rowspan="1">0.6</td>
<td colspan="1" rowspan="1">272×</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WALSHMCS001925C20">Parsons et al. 2016</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Acute lymphoblastic leukemia</td>
<td colspan="1" rowspan="1">
<italic>BRCA1</italic>
</td>
<td colspan="1" rowspan="1">Chr 17</td>
<td colspan="1" rowspan="1">41245200</td>
<td colspan="1" rowspan="1">AT</td>
<td colspan="1" rowspan="1">p.I783fs</td>
<td colspan="1" rowspan="1">Frameshift</td>
<td colspan="1" rowspan="1">WES</td>
<td colspan="1" rowspan="1">0.43</td>
<td colspan="1" rowspan="1">&gt;30×</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WALSHMCS001925C29">Zhang et al. 2015</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Acute lymphoblastic leukemia</td>
<td colspan="1" rowspan="1">
<italic>BRCA2</italic>
</td>
<td colspan="1" rowspan="1">Chr 13</td>
<td colspan="1" rowspan="1">32945092</td>
<td colspan="1" rowspan="1">G</td>
<td colspan="1" rowspan="1">p.W2830_E20splice</td>
<td colspan="1" rowspan="1">Splice</td>
<td colspan="1" rowspan="1">WES</td>
<td colspan="1" rowspan="1">0.51</td>
<td colspan="1" rowspan="1">&gt;30×</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WALSHMCS001925C29">Zhang et al. 2015</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Acute lymphoblastic leukemia</td>
<td colspan="1" rowspan="1">
<italic>BRCA2</italic>
</td>
<td colspan="1" rowspan="1">Chr 13</td>
<td colspan="1" rowspan="1">32968863</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">p.Y3098*</td>
<td colspan="1" rowspan="1">Nonsense</td>
<td colspan="1" rowspan="1">WES</td>
<td colspan="1" rowspan="1">0.51</td>
<td colspan="1" rowspan="1">&gt;30×</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WALSHMCS001925C29">Zhang et al. 2015</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Medulloblastoma</td>
<td colspan="1" rowspan="1">
<italic>BRCA2</italic>
</td>
<td colspan="1" rowspan="1">Chr 13</td>
<td colspan="1" rowspan="1">32929213</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">p.P2408fs</td>
<td colspan="1" rowspan="1">Frameshift</td>
<td colspan="1" rowspan="1">WGS</td>
<td colspan="1" rowspan="1">0.21</td>
<td colspan="1" rowspan="1">&gt;30×</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WALSHMCS001925C29">Zhang et al. 2015</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Medulloblastoma</td>
<td colspan="1" rowspan="1">
<italic>BRCA2</italic>
</td>
<td colspan="1" rowspan="1">Chr 13</td>
<td colspan="1" rowspan="1">32953932</td>
<td colspan="1" rowspan="1">T</td>
<td colspan="1" rowspan="1">p.L3000*</td>
<td colspan="1" rowspan="1">Nonsense</td>
<td colspan="1" rowspan="1">WGS</td>
<td colspan="1" rowspan="1">0.5</td>
<td colspan="1" rowspan="1">&gt;30×</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WALSHMCS001925C29">Zhang et al. 2015</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Neuroblastoma</td>
<td colspan="1" rowspan="1">
<italic>BRCA2</italic>
</td>
<td colspan="1" rowspan="1">Chr 13</td>
<td colspan="1" rowspan="1">32945092</td>
<td colspan="1" rowspan="1">G</td>
<td colspan="1" rowspan="1">p.W2830_E20splice</td>
<td colspan="1" rowspan="1">Splice</td>
<td colspan="1" rowspan="1">WES</td>
<td colspan="1" rowspan="1">0.43</td>
<td colspan="1" rowspan="1">&gt;30×</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WALSHMCS001925C29">Zhang et al. 2015</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Rhabdomyosarcoma</td>
<td colspan="1" rowspan="1">
<italic>BRCA2</italic>
</td>
<td colspan="1" rowspan="1">Chr 13</td>
<td colspan="1" rowspan="1">32911681</td>
<td colspan="1" rowspan="1">G</td>
<td colspan="1" rowspan="1">p.Q1063_S1064fs</td>
<td colspan="1" rowspan="1">Frameshift</td>
<td colspan="1" rowspan="1">WGS</td>
<td colspan="1" rowspan="1">0.37</td>
<td colspan="1" rowspan="1">&gt;30×</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WALSHMCS001925C29">Zhang et al. 2015</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>HGVS, Human Genome Variation Society.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Regardless, when mutations in these genes are revealed, there are implications for immediate family members. Standard of care dictates that testing for <italic>BRCA1/2</italic> mutations commences at age 25 yr in at-risk individuals with known familial mutations or family histories described as per the National Comprehensive Cancer Network (NCCN) guidelines and in some instances younger if this information will impact family planning. This standard is based on the premise that <italic>BRCA1/2</italic> mutations underpin cancers that arise in adulthood and the clinical benefits of this knowledge result from screening and risk-reductive surgeries occurring in adulthood (<xref ref-type="bibr" rid="WALSHMCS001925C1">Brooks et al. 2006</xref>). However, results from recent tumor-normal sequencing studies in pediatrics give pause and raise questions regarding the benefit of testing siblings of children diagnosed with cancer harboring <italic>BRCA</italic> mutations (<xref ref-type="table" rid="WALSHMCS001925TB1">Table 1</xref>).</p>
<p>In view of recent pediatric sequencing studies detecting children with germline <italic>BRCA1/2</italic> mutations across solid and liquid tumors, and the cases described here, pediatric oncologists should be linked with avenues to adult care for the potential screening, risk-reductive interventions (such as surgery), and family planning options currently available for parents of children carrying <italic>BRCA1/2</italic> mutations. For our patients, detection of previously unidentified heritable mutations prompted medical action and provided potentially lifesaving information.</p>
<p>It is important to note that numerous mutational platforms exist wherein tumors are profiled without corresponding normal DNA samples, rendering it difficult to assign certain mutations as somatic or germline. Moreover, in some institutions, germline mutations are subtracted from reporting if consent has not been obtained and may not be realized. These cases illustrate the importance that a corresponding normal DNA be reported to ensure accurate profiling and optimal care.</p>
</sec>
<sec id="s5">
<title>ADDITIONAL INFORMATION</title>
<sec id="s5a">
<title>Data Deposition and Access</title>
<p>Both variants described in this manuscript were deposited in ClinVar (<uri xlink:href="https://www.ncbi.nlm.nih.gov/clinvar">https://www.ncbi.nlm.nih.gov/clinvar</uri>) and were assigned the submission numbers SCV000564127 and SCV000564128 (<xref ref-type="bibr" rid="WALSHMCS001925C16">Landrum et al. 2016</xref>).</p>
</sec>
<sec id="s5b">
<title>Ethics Statement</title>
<p>Patients reported here provided written consent permitting use of molecular and phenotypic description under MSKCC's institutional review board (IRB)-approved studies #06-107 and #12-245.</p>
</sec>
<sec id="s5c">
<title>Acknowledgment</title>
<p>We thank Joseph Olechnowicz for editorial assistance.</p>
</sec>
<sec id="s5d">
<title>Author Contributions</title>
<p>M.F.W. and P.M. conceived the study. M.F.W., J.K., M.H., and K.O. performed clinical interpretation of the germline variants. All authors reviewed and drafted the manuscript.</p>
</sec>
<sec id="s5e">
<title>Funding</title>
<p>This research was funded in part through the National Institutes of Health/ National Cancer Institute (NIH/NCI) Cancer Center Support Grant P30 CA008748. M.F.W. receives research funding through the V Foundation Scholar Grant, Niehaus Center for Inherited Genomics, and the Crawford Fund for Pediatric Genomics.</p>
</sec>
<sec id="s5f">
<title>Competing Interest Statement</title>
<p>The authors have declared no competing interest.</p>
</sec>
</sec>
</body>
<back>
<ref-list>
<title>REFERENCES</title>
<ref id="WALSHMCS001925C1">
<mixed-citation publication-type="journal"><name><surname>Brooks</surname><given-names>GA</given-names></name>, <name><surname>Stopfer</surname><given-names>JE</given-names></name>, <name><surname>Erlichman</surname><given-names>J</given-names></name>, <name><surname>Davidson</surname><given-names>R</given-names></name>, <name><surname>Nathanson</surname><given-names>KL</given-names></name>, <name><surname>Domchek</surname><given-names>SM</given-names></name>. <year>2006</year>
<article-title>Childhood cancer in families with and without <italic>BRCA1</italic> or <italic>BRCA2</italic> mutations ascertained at a high-risk breast cancer clinic</article-title>. <source/>Cancer Biol Ther
<volume>5</volume>: <fpage>1098</fpage>–<lpage>1102</lpage>.<pub-id pub-id-type="pmid">16931905</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C2">
<mixed-citation publication-type="journal"><name><surname>Cheng</surname><given-names>DT</given-names></name>, <name><surname>Mitchell</surname><given-names>TN</given-names></name>, <name><surname>Zehir</surname><given-names>A</given-names></name>, <name><surname>Shah</surname><given-names>RH</given-names></name>, <name><surname>Benayed</surname><given-names>R</given-names></name>, <name><surname>Syed</surname><given-names>A</given-names></name>, <name><surname>Chandramohan</surname><given-names>R</given-names></name>, <name><surname>Liu</surname><given-names>ZY</given-names></name>, <name><surname>Won</surname><given-names>HH</given-names></name>, <name><surname>Scott</surname><given-names>SN</given-names></name>, <etal></etal>
<year>2015</year>
<article-title>Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology</article-title>. <source/>J Mol Diagn
<volume>17</volume>: <fpage>251</fpage>–<lpage>264</lpage>.<pub-id pub-id-type="pmid">25801821</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C3">
<mixed-citation publication-type="book"><name><surname>Daly</surname><given-names>M</given-names></name>, <name><surname>Sutcliffe</surname><given-names>J</given-names></name>, <name><surname>Gibbs</surname><given-names>R</given-names></name>, <name><surname>Buxbaum</surname><given-names>J</given-names></name>, <name><surname>Schellenberg</surname><given-names>G</given-names></name>. <source/>NIMH Data Archive. <publisher-name>National Institute of Mental Health</publisher-name>, <publisher-loc>Bethesda, MD</publisher-loc>; <comment><uri xlink:href="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000298.v2.p2">http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000298.v2.p2</uri></comment>
<pub-id pub-id-type="doi">10.15154/1163515</pub-id>
<date-in-citation content-type="access-date">Accessed March 28, 2017</date-in-citation>.</mixed-citation>
</ref>
<ref id="WALSHMCS001925C4">
<mixed-citation publication-type="journal"><name><surname>D'Andrea</surname><given-names>AD</given-names></name>, <name><surname>Grompe</surname><given-names>M</given-names></name>. <year>1997</year>
<article-title>Molecular biology of Fanconi anemia: implications for diagnosis and therapy</article-title>. <source/>Blood
<volume>90</volume>: <fpage>1725</fpage>–<lpage>1736</lpage>.<pub-id pub-id-type="pmid">9292505</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C5">
<mixed-citation publication-type="journal"><name><surname>D'Andrea</surname><given-names>AD</given-names></name>, <name><surname>Grompe</surname><given-names>M</given-names></name>. <year>2003</year>
<article-title>The Fanconi anaemia/BRCA pathway</article-title>. <source/>Nat Rev Cancer
<volume>3</volume>: <fpage>23</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">12509764</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C6">
<mixed-citation publication-type="journal"><name><surname>Dite</surname><given-names>GS</given-names></name>, <name><surname>Whittemore</surname><given-names>AS</given-names></name>, <name><surname>Knight</surname><given-names>JA</given-names></name>, <name><surname>John</surname><given-names>EM</given-names></name>, <name><surname>Milne</surname><given-names>RL</given-names></name>, <name><surname>Andrulis</surname><given-names>IL</given-names></name>, <name><surname>Southey</surname><given-names>MC</given-names></name>, <name><surname>McCredie</surname><given-names>MR</given-names></name>, <name><surname>Giles</surname><given-names>GG</given-names></name>, <name><surname>Miron</surname><given-names>A</given-names></name>, <etal></etal>
<year>2010</year>
<article-title>Increased cancer risks for relatives of very early-onset breast cancer cases with and without <italic>BRCA1</italic> and <italic>BRCA2</italic> mutations</article-title>. <source/>Br J Cancer
<volume>103</volume>: <fpage>1103</fpage>–<lpage>1108</lpage>.<pub-id pub-id-type="pmid">20877337</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C7">
<mixed-citation publication-type="journal"><name><surname>Downing</surname><given-names>JR</given-names></name>, <name><surname>Wilson</surname><given-names>RK</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Mardis</surname><given-names>ER</given-names></name>, <name><surname>Pui</surname><given-names>CH</given-names></name>, <name><surname>Ding</surname><given-names>L</given-names></name>, <name><surname>Ley</surname><given-names>TJ</given-names></name>, <name><surname>Evans</surname><given-names>WE</given-names></name>. <year>2012</year>
<article-title>The Pediatric Cancer Genome Project</article-title>. <source/>Nat Genet
<volume>44</volume>: <fpage>619</fpage>–<lpage>622</lpage>.<pub-id pub-id-type="pmid">22641210</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C8">
<mixed-citation publication-type="journal"><name><surname>Duran</surname><given-names>M</given-names></name>, <name><surname>Esteban-Cardeñosa</surname><given-names>E</given-names></name>, <name><surname>Velasco</surname><given-names>E</given-names></name>, <name><surname>Infante</surname><given-names>M</given-names></name>, <name><surname>Miner</surname><given-names>C</given-names></name>. <year>2003</year>
<article-title>Mutational analysis of <italic>BRCA2</italic> in Spanish breast cancer patients from Castilla-Leon: identification of four novel truncating mutations</article-title>. <source/>Hum Mutat
<volume>21</volume>: <fpage>448</fpage>.</mixed-citation>
</ref>
<ref id="WALSHMCS001925C9">
<mixed-citation publication-type="journal"><name><surname>Frampton</surname><given-names>GM</given-names></name>, <name><surname>Fichtenholtz</surname><given-names>A</given-names></name>, <name><surname>Otto</surname><given-names>GA</given-names></name>, <name><surname>Wang</surname><given-names>K</given-names></name>, <name><surname>Downing</surname><given-names>SR</given-names></name>, <name><surname>He</surname><given-names>J</given-names></name>, <name><surname>Schnall-Levin</surname><given-names>M</given-names></name>, <name><surname>White</surname><given-names>J</given-names></name>, <name><surname>Sanford</surname><given-names>EM</given-names></name>, <name><surname>An</surname><given-names>P</given-names></name>, <etal></etal>
<year>2013</year>
<article-title>Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing</article-title>. <source/>Nat Biotechnol
<volume>31</volume>: <fpage>1023</fpage>–<lpage>1031</lpage>.<pub-id pub-id-type="pmid">24142049</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C10">
<mixed-citation publication-type="journal"><collab>Genomes Project Consortium</collab>, <name><surname>Abecasis</surname><given-names>GR</given-names></name>, <name><surname>Altshuler</surname><given-names>D</given-names></name>, <name><surname>Auton</surname><given-names>A</given-names></name>, <name><surname>Brooks</surname><given-names>LD</given-names></name>, <name><surname>Durbin</surname><given-names>RM</given-names></name>, <name><surname>Gibbs</surname><given-names>RA</given-names></name>, <name><surname>Hurles</surname><given-names>ME</given-names></name>, <name><surname>McVean</surname><given-names>GA</given-names></name>. <year>2010</year>
<article-title>A map of human genome variation from population-scale sequencing</article-title>. <source/>Nature
<volume>467</volume>: <fpage>1061</fpage>–<lpage>1073</lpage>.<pub-id pub-id-type="pmid">20981092</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C11">
<mixed-citation publication-type="journal"><collab>Genomes Project Consortium</collab>, <name><surname>Auton</surname><given-names>A</given-names></name>, <name><surname>Brooks</surname><given-names>LD</given-names></name>, <name><surname>Durbin</surname><given-names>RM</given-names></name>, <name><surname>Garrison</surname><given-names>EP</given-names></name>, <name><surname>Kang</surname><given-names>HM</given-names></name>, <name><surname>Korbel</surname><given-names>JO</given-names></name>, <name><surname>Marchini</surname><given-names>JL</given-names></name>, <name><surname>McCarthy</surname><given-names>S</given-names></name>, <name><surname>McVean</surname><given-names>GA</given-names></name>, <etal></etal>
<year>2015</year>
<article-title>A global reference for human genetic variation</article-title>. <source/>Nature
<volume>526</volume>: <fpage>68</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">26432245</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C12">
<mixed-citation publication-type="journal"><name><surname>Green</surname><given-names>RC</given-names></name>, <name><surname>Berg</surname><given-names>JS</given-names></name>, <name><surname>Grody</surname><given-names>WW</given-names></name>, <name><surname>Kalia</surname><given-names>SS</given-names></name>, <name><surname>Korf</surname><given-names>BR</given-names></name>, <name><surname>Martin</surname><given-names>CL</given-names></name>, <name><surname>McGuire</surname><given-names>AL</given-names></name>, <name><surname>Nussbaum</surname><given-names>RL</given-names></name>, <name><surname>O'Daniel</surname><given-names>JM</given-names></name>, <name><surname>Ormond</surname><given-names>KE</given-names></name>, <etal></etal>
<year>2013</year>
<article-title>ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing</article-title>. <source/>Genet Med
<volume>15</volume>: <fpage>565</fpage>–<lpage>574</lpage>.<pub-id pub-id-type="pmid">23788249</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C13">
<mixed-citation publication-type="journal"><name><surname>Hirsch</surname><given-names>B</given-names></name>, <name><surname>Shimamura</surname><given-names>A</given-names></name>, <name><surname>Moreau</surname><given-names>L</given-names></name>, <name><surname>Baldinger</surname><given-names>S</given-names></name>, <name><surname>Hag-alshiekh</surname><given-names>M</given-names></name>, <name><surname>Bostrom</surname><given-names>B</given-names></name>, <name><surname>Sencer</surname><given-names>S</given-names></name>, <name><surname>D'Andrea</surname><given-names>AD</given-names></name>. <year>2004</year>
<article-title>Association of biallelic <italic>BRCA2/FANCD1</italic> mutations with spontaneous chromosomal instability and solid tumors of childhood</article-title>. <source/>Blood
<volume>103</volume>: <fpage>2554</fpage>–<lpage>2559</lpage>.<pub-id pub-id-type="pmid">14670928</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C14">
<mixed-citation publication-type="journal"><name><surname>Howlett</surname><given-names>NG</given-names></name>, <name><surname>Taniguchi</surname><given-names>T</given-names></name>, <name><surname>Olson</surname><given-names>S</given-names></name>, <name><surname>Cox</surname><given-names>B</given-names></name>, <name><surname>Waisfisz</surname><given-names>Q</given-names></name>, <name><surname>De Die-Smulders</surname><given-names>C</given-names></name>, <name><surname>Persky</surname><given-names>N</given-names></name>, <name><surname>Grompe</surname><given-names>M</given-names></name>, <name><surname>Joenje</surname><given-names>H</given-names></name>, <name><surname>Pals</surname><given-names>G</given-names></name>, <etal></etal>
<year>2002</year>
<article-title>Biallelic inactivation of <italic>BRCA2</italic> in Fanconi anemia</article-title>. <source/>Science
<volume>297</volume>: <fpage>606</fpage>–<lpage>609</lpage>.<pub-id pub-id-type="pmid">12065746</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C15">
<mixed-citation publication-type="journal"><name><surname>Kauff</surname><given-names>ND</given-names></name>, <name><surname>Scheuer</surname><given-names>L</given-names></name>, <name><surname>Robson</surname><given-names>ME</given-names></name>, <name><surname>Glogowski</surname><given-names>E</given-names></name>, <name><surname>Kelly</surname><given-names>B</given-names></name>, <name><surname>Barakat</surname><given-names>R</given-names></name>, <name><surname>Heerdt</surname><given-names>A</given-names></name>, <name><surname>Borgen</surname><given-names>PI</given-names></name>, <name><surname>Davis</surname><given-names>JG</given-names></name>, <name><surname>Offit</surname><given-names>K</given-names></name>. <year>2001</year>
<article-title>Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with <italic>BRCA1</italic> or <italic>BRCA2</italic> mutations</article-title>. <source/>Genet Med
<volume>3</volume>: <fpage>422</fpage>–<lpage>425</lpage>.<pub-id pub-id-type="pmid">11715007</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C16">
<mixed-citation publication-type="journal"><name><surname>Landrum</surname><given-names>MJ</given-names></name>, <name><surname>Lee</surname><given-names>JM</given-names></name>, <name><surname>Benson</surname><given-names>M</given-names></name>, <name><surname>Brown</surname><given-names>G</given-names></name>, <name><surname>Chao</surname><given-names>C</given-names></name>, <name><surname>Chitipiralla</surname><given-names>S</given-names></name>, <name><surname>Gu</surname><given-names>B</given-names></name>, <name><surname>Hart</surname><given-names>J</given-names></name>, <name><surname>Hoffman</surname><given-names>D</given-names></name>, <name><surname>Hoover</surname><given-names>J</given-names></name>, <etal></etal>
<year>2016</year>
<article-title>ClinVar: public archive of interpretations of clinically relevant variants</article-title>. <source/>Nucleic Acids Res
<volume>44</volume>: <fpage>D862</fpage>–<lpage>D868</lpage>.<pub-id pub-id-type="pmid">26582918</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C17">
<mixed-citation publication-type="journal"><name><surname>Mody</surname><given-names>RJ</given-names></name>, <name><surname>Wu</surname><given-names>YM</given-names></name>, <name><surname>Lonigro</surname><given-names>RJ</given-names></name>, <name><surname>Cao</surname><given-names>X</given-names></name>, <name><surname>Roychowdhury</surname><given-names>S</given-names></name>, <name><surname>Vats</surname><given-names>P</given-names></name>, <name><surname>Frank</surname><given-names>KM</given-names></name>, <name><surname>Prensner</surname><given-names>JR</given-names></name>, <name><surname>Asangani</surname><given-names>I</given-names></name>, <name><surname>Palanisamy</surname><given-names>N</given-names></name>, <etal></etal>
<year>2015</year>
<article-title>Integrative clinical sequencing in the management of refractory or relapsed cancer in youth</article-title>. <source/>JAMA
<volume>314</volume>: <fpage>913</fpage>–<lpage>925</lpage>.<pub-id pub-id-type="pmid">26325560</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C18">
<mixed-citation publication-type="journal"><name><surname>Neuhausen</surname><given-names>S</given-names></name>, <name><surname>Gilewski</surname><given-names>T</given-names></name>, <name><surname>Norton</surname><given-names>L</given-names></name>, <name><surname>Tran</surname><given-names>T</given-names></name>, <name><surname>McGuire</surname><given-names>P</given-names></name>, <name><surname>Swensen</surname><given-names>J</given-names></name>, <name><surname>Hampel</surname><given-names>H</given-names></name>, <name><surname>Borgen</surname><given-names>P</given-names></name>, <name><surname>Brown</surname><given-names>K</given-names></name>, <name><surname>Skolnick</surname><given-names>M</given-names></name>, <etal></etal>
<year>1996</year>
<article-title>Recurrent <italic>BRCA2</italic> 6174delT mutations in Ashkenazi Jewish women affected by breast cancer</article-title>. <source/>Nat Genet
<volume>13</volume>: <fpage>126</fpage>–<lpage>128</lpage>.<pub-id pub-id-type="pmid">8673092</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C19">
<mixed-citation publication-type="journal"><name><surname>Offit</surname><given-names>K</given-names></name>, <name><surname>Levran</surname><given-names>O</given-names></name>, <name><surname>Mullaney</surname><given-names>B</given-names></name>, <name><surname>Mah</surname><given-names>K</given-names></name>, <name><surname>Nafa</surname><given-names>K</given-names></name>, <name><surname>Batish</surname><given-names>SD</given-names></name>, <name><surname>Diotti</surname><given-names>R</given-names></name>, <name><surname>Schneider</surname><given-names>H</given-names></name>, <name><surname>Deffenbaugh</surname><given-names>A</given-names></name>, <name><surname>Scholl</surname><given-names>T</given-names></name>, <etal></etal>
<year>2003</year>
<article-title>Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia</article-title>. <source/>J Natl Cancer Inst
<volume>95</volume>: <fpage>1548</fpage>–<lpage>1551</lpage>.<pub-id pub-id-type="pmid">14559878</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C20">
<mixed-citation publication-type="journal"><name><surname>Parsons</surname><given-names>DW</given-names></name>, <name><surname>Roy</surname><given-names>A</given-names></name>, <name><surname>Yang</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>T</given-names></name>, <name><surname>Scollon</surname><given-names>S</given-names></name>, <name><surname>Bergstrom</surname><given-names>K</given-names></name>, <name><surname>Kerstein</surname><given-names>RA</given-names></name>, <name><surname>Gutierrez</surname><given-names>S</given-names></name>, <name><surname>Petersen</surname><given-names>AK</given-names></name>, <name><surname>Bavle</surname><given-names>A</given-names></name>, <etal></etal>
<year>2016</year>
<article-title>Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors</article-title>. <source/>JAMA Oncol
<pub-id pub-id-type="doi">10.1001/jamaoncol.2015.5699</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C21">
<mixed-citation publication-type="journal"><name><surname>Pritchard</surname><given-names>CC</given-names></name>, <name><surname>Mateo</surname><given-names>J</given-names></name>, <name><surname>Walsh</surname><given-names>MF</given-names></name>, <name><surname>De Sarkar</surname><given-names>N</given-names></name>, <name><surname>Abida</surname><given-names>W</given-names></name>, <name><surname>Beltran</surname><given-names>H</given-names></name>, <name><surname>Garofalo</surname><given-names>A</given-names></name>, <name><surname>Gulati</surname><given-names>R</given-names></name>, <name><surname>Carreira</surname><given-names>S</given-names></name>, <name><surname>Eeles</surname><given-names>R</given-names></name>, <etal></etal>
<year>2016</year>
<article-title>Inherited DNA-repair gene mutations in men with metastatic prostate cancer</article-title>. <source/>N Engl J Med
<volume>375</volume>: <fpage>443</fpage>–<lpage>453</lpage>.<pub-id pub-id-type="pmid">27433846</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C22">
<mixed-citation publication-type="journal"><name><surname>Rebbeck</surname><given-names>TR</given-names></name>, <name><surname>Friebel</surname><given-names>TM</given-names></name>, <name><surname>Mitra</surname><given-names>N</given-names></name>, <name><surname>Wan</surname><given-names>F</given-names></name>, <name><surname>Chen</surname><given-names>S</given-names></name>, <name><surname>Andrulis</surname><given-names>IL</given-names></name>, <name><surname>Apostolou</surname><given-names>P</given-names></name>, <name><surname>Arnold</surname><given-names>N</given-names></name>, <name><surname>Arun</surname><given-names>BK</given-names></name>, <name><surname>Barrowdale</surname><given-names>D</given-names></name>, <etal></etal>
<year>2016</year>
<article-title>Inheritance of deleterious mutations at both <italic>BRCA1</italic> and <italic>BRCA2</italic> in an international sample of 32,295 women</article-title>. <source/>Breast Cancer Res
<volume>18</volume>: <fpage>112</fpage>.<pub-id pub-id-type="pmid">27836010</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C23">
<mixed-citation publication-type="journal"><name><surname>Sawyer</surname><given-names>SL</given-names></name>, <name><surname>Tian</surname><given-names>L</given-names></name>, <name><surname>Kahkönen</surname><given-names>M</given-names></name>, <name><surname>Schwartzentruber</surname><given-names>J</given-names></name>, <name><surname>Kircher</surname><given-names>M</given-names></name>, <collab>University of Washington Centre for Mendelian Genomics; FORGE Canada Consortium</collab>, <name><surname>Majewski</surname><given-names>J</given-names></name>, <name><surname>Dyment</surname><given-names>DA</given-names></name>, <name><surname>Innes</surname><given-names>AM</given-names></name>, <etal></etal>
<year>2015</year>
<article-title>Biallelic mutations in <italic>BRCA1</italic> cause a new Fanconi anemia subtype</article-title>. <source/>Cancer Discov
<volume>5</volume>: <fpage>135</fpage>–<lpage>142</lpage>.<pub-id pub-id-type="pmid">25472942</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C24">
<mixed-citation publication-type="journal"><name><surname>Schrader</surname><given-names>KA</given-names></name>, <name><surname>Cheng</surname><given-names>DT</given-names></name>, <name><surname>Joseph</surname><given-names>V</given-names></name>, <name><surname>Prasad</surname><given-names>M</given-names></name>, <name><surname>Walsh</surname><given-names>M</given-names></name>, <name><surname>Zehir</surname><given-names>A</given-names></name>, <name><surname>Ni</surname><given-names>A</given-names></name>, <name><surname>Thomas</surname><given-names>T</given-names></name>, <name><surname>Benayed</surname><given-names>R</given-names></name>, <name><surname>Ashraf</surname><given-names>A</given-names></name>, <etal></etal>
<year>2016</year>
<article-title>Germline variants in targeted tumor sequencing using matched normal DNA</article-title>. <source/>JAMA Oncol
<volume>2</volume>: <fpage>104</fpage>–<lpage>111</lpage>.<pub-id pub-id-type="pmid">26556299</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C25">
<mixed-citation publication-type="journal"><name><surname>Spurdle</surname><given-names>AB</given-names></name>, <name><surname>Healey</surname><given-names>S</given-names></name>, <name><surname>Devereau</surname><given-names>A</given-names></name>, <name><surname>Hogervorst</surname><given-names>FBL</given-names></name>, <name><surname>Monteiro</surname><given-names>ANA</given-names></name>, <name><surname>Nathanson</surname><given-names>KL</given-names></name>, <name><surname>Radice</surname><given-names>P</given-names></name>, <name><surname>Stoppa-Lyonnet</surname><given-names>D</given-names></name>, <name><surname>Tavtigian</surname><given-names>S</given-names></name>, <name><surname>Wappenschmidt</surname><given-names>B</given-names></name>, <etal></etal>
<year>2012</year>
<article-title>ENIGMA-evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in <italic>BRCA1</italic> and <italic>BRCA2</italic> genes</article-title>. <source/>Hum Mutat
<volume>33</volume>: <fpage>2</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">21990146</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C26">
<mixed-citation publication-type="journal"><name><surname>Susswein</surname><given-names>LR</given-names></name>, <name><surname>Marshall</surname><given-names>ML</given-names></name>, <name><surname>Nusbaum</surname><given-names>R</given-names></name>, <name><surname>Vogel Postula</surname><given-names>KJ</given-names></name>, <name><surname>Weissman</surname><given-names>SM</given-names></name>, <name><surname>Yackowski</surname><given-names>L</given-names></name>, <name><surname>Vaccari</surname><given-names>EM</given-names></name>, <name><surname>Bissonnette</surname><given-names>J</given-names></name>, <name><surname>Booker</surname><given-names>JK</given-names></name>, <name><surname>Cremona</surname><given-names>ML</given-names></name>, <etal></etal>
<year>2016</year>
<article-title>Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing</article-title>. <source/>Genet Med
<volume>18</volume>: <fpage>823</fpage>–<lpage>832</lpage>.<pub-id pub-id-type="pmid">26681312</pub-id></mixed-citation>
</ref>
<ref id="WALSHMCS001925C27">
<mixed-citation publication-type="journal"><name><surname>Walsh</surname><given-names>MF</given-names></name>, <name><surname>Wu</surname><given-names>G</given-names></name>, <name><surname>Edmonson</surname><given-names>M</given-names></name>, <name><surname>Gruber</surname><given-names>TA</given-names></name>, <name><surname>Easton</surname><given-names>J</given-names></name>, <name><surname>Yergeau</surname><given-names>D</given-names></name>, <name><surname>Vadodaria</surname><given-names>B</given-names></name>, <name><surname>Ma</surname><given-names>XT</given-names></name>, <name><surname>Chen</surname><given-names>X</given-names></name>, <name><surname>Mcgee</surname><given-names>R</given-names></name>, <etal></etal>
<year>2014</year>
<article-title>Incidence of germline mutations in cancer-predisposition genes in children with hematologic malignancies: a report from the pediatric cancer genome project</article-title>. <source/>Blood
<volume>124</volume>: <fpage>127</fpage>.</mixed-citation>
</ref>
<ref id="WALSHMCS001925C28">
<mixed-citation publication-type="confproc"><name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>Wilson</surname><given-names>CL</given-names></name>, <name><surname>Easton</surname><given-names>J</given-names></name>, <name><surname>Hedges</surname><given-names>D</given-names></name>, <name><surname>Liu</surname><given-names>Q</given-names></name>, <name><surname>Wu</surname><given-names>G</given-names></name>, <name><surname>Rusch</surname><given-names>M</given-names></name>, <name><surname>Edmonson</surname><given-names>M</given-names></name>, <name><surname>Levy</surname><given-names>S</given-names></name>, <name><surname>Lanctot</surname><given-names>JQ</given-names></name>, <etal></etal>
<year>2017</year>
<article-title>Germline mutations in cancer predisposition genes and risk for subsequent neoplasms among long-term survivors of childhood cancer in the St. Jude Lifetime Cohort</article-title>. In <conf-name>Proceedings of the 107th Annual Meeting of the American Association for Cancer Research</conf-name>; <conf-date>2017 Apr 1–5</conf-date>; <comment>AACR; 2017, Washington, DC. Philadelphia, PA. Abstract 3001</comment></mixed-citation>
</ref>
<ref id="WALSHMCS001925C29">
<mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Walsh</surname><given-names>MF</given-names></name>, <name><surname>Wu</surname><given-names>G</given-names></name>, <name><surname>Edmonson</surname><given-names>MN</given-names></name>, <name><surname>Gruber</surname><given-names>TA</given-names></name>, <name><surname>Easton</surname><given-names>J</given-names></name>, <name><surname>Hedges</surname><given-names>D</given-names></name>, <name><surname>Ma</surname><given-names>X</given-names></name>, <name><surname>Zhou</surname><given-names>X</given-names></name>, <name><surname>Yergeau</surname><given-names>DA</given-names></name>, <etal></etal>
<year>2015</year>
<article-title>Germline mutations in predisposition genes in pediatric cancer</article-title>. <source/>N Engl J Med
<volume>373</volume>: <fpage>2336</fpage>–<lpage>2346</lpage>.<pub-id pub-id-type="pmid">26580448</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>